Observational studyBMC nephrology2021
Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre.
Observational study in BMC nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- Drug-Induced Thrombotic Microangiopathy in Patients with Cancer : A Clinicopathologic Series.Kidney360 · 2026Article
- Drug-Induced Thrombotic Microangiopathy in Cancer: Can Kidney Biopsy Help Unravel This Highly Heterogeneous Pathologic Entity?Kidney360 · 2026Article
- Gemcitabine-sirolimus synergy associated thrombotic microangiopathy in a renal transplant recipient with mesenteric leiomyosarcoma: A case report.World journal of transplantation · 2026Article
- Knowledge mapping and visualized analysis of research progress in onconephrology: a bibliometric analysis.Renal failure · 2025Article
- Thrombotic Microangiopathy From Peptide Receptor Radionuclide Therapy.Kidney international reports · 2025Article
- Thrombotic Microangiopathy (TMA) in a Heart Transplant Patient: A Complex Clinical-Pathologic Dilemma.Case reports in medicine · 2025Article
- A rare complication of thrombotic microangiopathy induced by chemotherapy for second breast cancer in a Hodgkin lymphoma survivor: a case report.AME case reports · 2025Article
- The complement C3a/C3aR pathway is associated with treatment resistance to gemcitabine-based neoadjuvant therapy in pancreatic cancer.Computational and structural biotechnology journal · 2024Article
- SUrvey of renal Biopsy registry database and Anticancer dRUg therapy in Japan (SUBARU-J study).Clinical kidney journal · 2024Article
- Thrombotic Microangiopathy After Long-Lasting Treatment by Gemcitabine: Description, Evolution and Treatment of a Rare Case.Journal of medical cases · 2024Article
- Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system.Frontiers in pharmacology · 2024Article
- Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition.BMC nephrology · 2023Article
- Nephrotoxicity associated with anticancer agents: perspective on onconephrology from nephrologists.International journal of clinical oncology · 2023Review
- Peering into the darkness of drug-induced thrombotic microangiopathy: complement, are you in there?Journal of gastrointestinal oncology · 2023Article
- Clinical characteristics, treatments, and outcomes of interferon-beta-induced thrombotic microangiopathy: a literature-based retrospective analysis.Therapeutic advances in neurological disorders · 2023Article
- Gemcitabine-induced thrombotic microangiopathy treated with eculizumab: a case report.Journal of gastrointestinal oncology · 2022Article
- Thrombotic microangiopathy (TMA) in adult patients with solid tumors: a challenging complication in the era of emerging anticancer therapies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Review
- Acute kidney injury in pediatric hematopoietic cell transplantation: critical appraisal and consensus.Pediatric nephrology (Berlin, Germany) · 2022Review
- Drug-induced thrombotic microangiopathy: An updated review of causative drugs, pathophysiology, and management.Frontiers in pharmacology · 2022Review
- Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre.BMC nephrology · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGemcitabine is a broadly prescribed chemotherapy, the use of which can be limited by renal adverse events, including thrombotic microangiopathy (TMA).
methodsThis study evaluated the efficacy of eculizumab, a monoclonal antibody targeting the terminal complement pathway, in patients with gemcitabine-induced TMA (G-TMA). We conducted an observational, retrospective, multicenter study in 5 French centres, between 2011 and 2016.
resultsTwelve patients with a G-TMA treated by eculizumab were included. The main characteristics were acute renal failure (100%), including stage 3 acute kidney injury (AKI, 58%) and renal replacement therapy (17%), hypertension (92%) and diffuse oedema (83%). Eculizumab was started after a median of 15 days (range 4-44) following TMA diagnosis. A median of 4 injections of eculizumab was performed (range 2-22). Complete hematological remission was achieved in 10 patients (83%) and blood transfusion significantly decreased after only one injection of eculizumab (median of 3 packed red blood cells (range 0-10) before treatment vs 0 (range 0-1) after one injection, P < 0.001). Two patients recovered completely renal function (17%), and 8 achieved a partial remission (67%). Compared to a control group of G-TMA without use of eculizumab, renal outcome was more favourable. At the end of the follow up, median eGFR was 45 vs 33 ml/min/1.73m
conclusionsThese results suggest that eculizumab is efficient on haemolysis and reduces transfusion requirement in G-TMA. Moreover, eculizumab may improve renal function recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.